Hyperinsulinemia – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
This report provides top-line data relating to the clinical trials on hyperinsulinemia. The report includes an overview of trials count and their average enrollment in top countries conducted globally. It includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. Moreover, the report also provides prominent drug names and trial counts for in-progress trials (based on the number of ongoing trials).
Hyperinsulinemia clinical trial report consists of 106 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, and Phase I stand at 2, 7, 16, and 21 respectively. Similarly, the trials with different status compile of Completed – 75, Ongoing – 13, Planned – 5, Terminated – 3, and Withdrawn – 10. Out of 75 completed trials, 41 trials have achieved end point(s). GlobalData’s Clinical Trials Database features trials from across the globe covering more than 20 therapy areas and nearly 2,000 indications.
What are the top regions and countries in the global hyperinsulinemia clinical trials market?
In total there were 106 clinical trials conducted on hyperinsulinemia, as of December 2021, of these 40 clinical trials were in North America. In the country-wise analysis, the US has the highest number of hyperinsulinemia clinical trials while China has the highest average patient enrollment in hyperinsulinemia clinical trials.
North America: North America accounted for the highest number of hyperinsulinemia clinical trials. The US-led the hyperinsulinemia clinical trials market, while Mexico and Canada accounted for the second and third highest number of hyperinsulinemia clinical trials.
Asia-Pacific: Asia-pacific has covered the third-highest number of clinical trials. In the Asia-Pacific region, China has the highest number of hyperinsulinemia clinical trials, followed by Japan, India, Indonesia, and South Korea.
Europe: Europe holds the second position as per the number of trials in the hyperinsulinemia clinical trials market after North America. Among the European countries, the UK has the highest number of hyperinsulinemia clinical trials, followed by Spain, Germany, Italy, and France.
Middle East and Africa: Israel has the highest number of hyperinsulinemia clinical trials, followed by Saudi Arabia. More than 5 trials have been conducted in the Middle East and Africa.
G7 countries: Among the G7 (the US, the UK, Germany, France, Italy, Canada, and Japan) countries, France has the highest proportion of hyperinsulinemia to metabolic disorders clinical trials, followed by the UK, the US, Italy, Germany, Japan, and Canada. However, the US has the highest number of hyperinsulinemia clinical trials.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Indonesia has the highest proportion of hyperinsulinemia to metabolic disorders clinical trials, followed by China, Turkey, Mexico, Russia, India, and Brazil. However, China has the highest number of hyperinsulinemia clinical trials.
Global hyperinsulinemia clinical trials market, by region
For more regional insights, download a free report sample
What are the different phases in the global hyperinsulinemia clinical trials market?
There are predominantly four phases in the global hyperinsulinemia clinical trials market. In E7 countries, phase I has got the highest number of clinical trials for the treatment of hyperinsulinemia. As of December 2021, there were more than 50 clinical trials in Phase II, of which five clinical trials were in progress for the time period of 1995-2021. There were more than 10 clinical trials in progress of which a significant percentage was in phase II study.
Which are the key sponsors in the global hyperinsulinemia clinical trials market?
Eiger BioPharmaceuticals Inc, XOMA Corp, Crinetics Pharmaceuticals Inc, Hanmi Science Co Ltd, Novartis AG, XERIS Pharmaceuticals Inc, Zealand Pharma AS, F. Hoffmann-La Roche Ltd, Rezolute Inc, and Sermes Planificacion SL are the key sponsors in the global hyperinsulinemia clinical trials market.
Global hyperinsulinemia clinical trials market, by key sponsors
For more key sponsor insights, download a free report sample
Market report scope
Key regions | Asia-Pacific, Europe, North America, Middle East and Africa |
Key countries | The US, China, The UK, Spain, France, Germany, Italy, Israel, the Netherlands, and Japan |
Key sponsors | Eiger BioPharmaceuticals Inc, XOMA Corp, Crinetics Pharmaceuticals Inc, Hanmi Science Co Ltd, Novartis AG, XERIS Pharmaceuticals Inc, Zealand Pharma AS, F. Hoffmann-La Roche Ltd, Rezolute Inc, and Sermes Planificacion SL |
Scope
- The report provides a snapshot of the global clinical trials landscape.
- Report provides the top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end point status.
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment.
- The report provides enrollment trends for the past five years.
- Report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level.
XOMA Corp
Crinetics Pharmaceuticals Inc
Hanmi Science Co Ltd
Novartis AG
XERIS Pharmaceuticals Inc
Zealand Pharma AS
F. Hoffmann-La Roche Ltd
Rezolute Inc
Sermes Planificacion SL
Table of Contents
Table
Figures
Frequently asked questions
-
Which are the key regions in the global hyperinsulinemia clinical trials market?
The key regions in the global hyperinsulinemia clinical trials market are Asia-Pacific, Europe, North America, and the Middle East and Africa.
-
Which are the key countries in the global hyperinsulinemia clinical trials market?
The key countries in the global hyperinsulinemia clinical trials market are the US, China, the UK, Spain, France, Germany, Italy, Israel, the Netherlands, and Japan.
-
Which are the key sponsors in the global hyperinsulinemia clinical trials market?
Eiger BioPharmaceuticals Inc, XOMA Corp, Crinetics Pharmaceuticals Inc, Hanmi Science Co Ltd, Novartis AG, XERIS Pharmaceuticals Inc, Zealand Pharma AS, F. Hoffmann-La Roche Ltd, Rezolute Inc, and Sermes Planificacion SL are the key sponsors in the global hyperinsulinemia clinical trials market.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Metabolic Disorders reportsHyperinsulinemia – Global Clinical Trials Review, H1, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData's clinical trial report, “Hyperinsulinemia – Global Clinical Trials Review, H1, 2021" provides an overview of Hyperinsulinemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperinsulinemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
XOMA Corp
Crinetics Pharmaceuticals Inc
Hanmi Science Co Ltd
Novartis AG
XERIS Pharmaceuticals Inc
Zealand Pharma AS
F. Hoffmann-La Roche Ltd
Rezolute Inc
Sermes Planificacion SL
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.